Given thesuccess of the marketed antibody drugs secukinumab (Cosentyx) andixekizumab (Talz) in psoriasis, psoriatic arthritis, and ankylosingspondylitis, the race to a commercial small-molecule IL-17a antagonisthas started (Figure 1). Here, IL17A is linked to psoriasis.